Format
Sort by

Send to

Choose Destination

Search results

Items: 20

1.

Mud-bath therapy in addition to usual care in bilateral knee osteoarthritis: Economic evaluation alongside a randomized controlled trial.

Ciani O, Pascarelli NA, Giannitti C, Galeazzi M, Meregaglia M, Fattore G, Fioravanti A.

Arthritis Care Res (Hoboken). 2016 Oct 9. doi: 10.1002/acr.23116. [Epub ahead of print]

PMID:
27723261
2.

A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis.

Cervigni M, Sommariva M, Tenaglia R, Porru D, Ostardo E, Giammò A, Trevisan S, Frangione V, Ciani O, Tarricone R, Pappagallo GL.

Neurourol Urodyn. 2016 Sep 21. doi: 10.1002/nau.23091. [Epub ahead of print]

PMID:
27654012
3.

Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses.

Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V.

Oncotarget. 2016 Aug 26. doi: 10.18632/oncotarget.11644. [Epub ahead of print]

4.

Use of surrogate end points in healthcare policy: a proposal for adoption of a validation framework.

Ciani O, Buyse M, Drummond M, Rasi G, Saad ED, Taylor RS.

Nat Rev Drug Discov. 2016 Jul;15(7):516. doi: 10.1038/nrd.2016.81. No abstract available.

PMID:
27256477
5.

Intravesical administration of combined hyaluronic acid (HA) and chondroitin sulfate (CS) for the treatment of female recurrent urinary tract infections: a European multicentre nested case-control study.

Ciani O, Arendsen E, Romancik M, Lunik R, Costantini E, Di Biase M, Morgia G, FragalĂ  E, Roman T, Bernat M, Guazzoni G, Tarricone R, Lazzeri M.

BMJ Open. 2016 Mar 31;6(3):e009669. doi: 10.1136/bmjopen-2015-009669.

6.

Validation of surrogate end points for overall survival in advanced colorectal cancer: A harmonized approach is needed.

Ciani O, Taylor RS.

J Clin Epidemiol. 2016 Feb;70:277-8. doi: 10.1016/j.jclinepi.2015.08.020. No abstract available.

PMID:
26348801
7.

Health technology assessment of medical devices: a survey of non-European union agencies.

Ciani O, Wilcher B, Blankart CR, Hatz M, Rupel VP, Erker RS, Varabyova Y, Taylor RS.

Int J Technol Assess Health Care. 2015 Jan;31(3):154-65. doi: 10.1017/S0266462315000185.

8.

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R.

Breast Cancer Res Treat. 2015 Jul;152(1):95-117. doi: 10.1007/s10549-015-3453-9.

PMID:
26044370
9.

Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer.

Ciani O, Buyse M, Garside R, Peters J, Saad ED, Stein K, Taylor RS.

J Clin Epidemiol. 2015 Jul;68(7):833-42. doi: 10.1016/j.jclinepi.2015.02.016. Review.

10.

The role of health technology assessment bodies in shaping drug development.

Ciani O, Jommi C.

Drug Des Devel Ther. 2014 Nov 10;8:2273-81. doi: 10.2147/DDDT.S49935.

11.

Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.

Ciani O, Davis S, Tappenden P, Garside R, Stein K, Cantrell A, Saad ED, Buyse M, Taylor RS.

Int J Technol Assess Health Care. 2014 Jul;30(3):312-24. doi: 10.1017/S0266462314000300. Review.

PMID:
25308694
12.

Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis.

Taylor RS, Piepoli MF, Smart N, Coats AJ, Ellis S, Dalal H, O'Connor CM, Warren FC, Whellan D, Ciani O; ExTraMATCH II Collaborators..

Int J Cardiol. 2014 Jul 1;174(3):683-7. doi: 10.1016/j.ijcard.2014.04.203. Erratum in: Int J Cardiol. 2015 Aug 15;193:93.

PMID:
24804902
13.

An economic perspective on urinary tract infection: the "costs of resignation".

Ciani O, Grassi D, Tarricone R.

Clin Drug Investig. 2013 Apr;33(4):255-61. doi: 10.1007/s40261-013-0069-x.

PMID:
23475540
14.

Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological study.

Ciani O, Buyse M, Garside R, Pavey T, Stein K, Sterne JA, Taylor RS.

BMJ. 2013 Jan 29;346:f457. doi: 10.1136/bmj.f457. Review.

15.

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Pavey T, Hoyle M, Ciani O, Crathorne L, Jones-Hughes T, Cooper C, Osipenko L, Venkatachalam M, Rudin C, Ukoumunne O, Garside R, Anderson R.

Health Technol Assess. 2012;16(42):iii-iv, 1-277. doi: 10.3310/hta16420. Review.

16.

Diffusion and use of health technology assessment in policy making: what lessons for decentralised healthcare systems?

Ciani O, Tarricone R, Torbica A.

Health Policy. 2012 Dec;108(2-3):194-202. doi: 10.1016/j.healthpol.2012.09.017.

PMID:
23093020
17.

Determinants of demand for total hip and knee arthroplasty: a systematic literature review.

Mota RE, Tarricone R, Ciani O, Bridges JF, Drummond M.

BMC Health Serv Res. 2012 Jul 30;12:225. doi: 10.1186/1472-6963-12-225. Review.

18.

Surrogate, friend or foe? The need for case studies of the use of surrogate outcomes in cost-effectiveness analyses.

Ciani O, Taylor RS.

Health Econ. 2013 Feb;22(2):251-2. doi: 10.1002/hec.2826.

PMID:
22623328
19.

A more evidence based approach to the use of surrogate end points in policy making.

Ciani O, Taylor RS.

BMJ. 2011 Oct 25;343:d6498. doi: 10.1136/bmj.d6498. No abstract available.

PMID:
22027353
20.

Pervasive technology in Neonatal Intensive Care Unit: a prototype for newborns unobtrusive monitoring.

Ciani O, Piccini L, Parini S, Rullo A, Bagnoli F, Marti P, Andreoni G.

Conf Proc IEEE Eng Med Biol Soc. 2008;2008:1292-5. doi: 10.1109/IEMBS.2008.4649400.

PMID:
19162903
Items per page

Supplemental Content

Support Center